Switchable Fluorescence of Doxorubicin for Label-Free Imaging of Bioorthogonal Drug Release.

ABSTRACT: Monitoring the release and activation of prodrug formulations provides essential information about the outcome of a therapy. While the prodrug delivery can be confirmed by using different imaging techniques, confirming the release of active payload by using imaging is a challenge. Here, we have discovered that the switchable fluorescence of doxorubicin can validate drug release upon its uncaging reaction with a highly specific chemical partner. We have observed that the conjugation of doxorubicin with a trans-cyclooctene (TCO) diminishes its fluorescence at 595 nm. This quenched fluorescence of the doxorubicin prodrug is recovered upon its bond-cleaving reaction with tetrazine. Clinically assessed iron oxide nanoparticles were used to formulate a doxorubicin nanodrug. The release of doxoru

SUBMITTER: Uyar TB 

PROVIDER: S-EPMC7397846 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature